- •Uveitis
- •Foreword
- •Preface
- •Dedication
- •Acknowledgments
- •Elements of the Immune System and Concepts of Intraocular Inflammatory Disease Pathogenesis
- •Elements of the immune system
- •Macrophages/monocytes
- •Dendritic cells
- •T cells
- •Major subsets of T cells
- •Cytokines
- •T-cell subsets
- •T-regulatory cells
- •T-cell receptor
- •Chemokines
- •Thymic expression and central immune tolerance
- •B cells
- •Classes of Immunoglobulin
- •Other cells
- •Mast Cells
- •Eosinophils
- •Neutrophils
- •Resident Ocular Cells
- •Complement system
- •Cellular interactions: hypersensitivity reactions
- •Classic immune hypersensitivity reactions
- •Type I
- •Type II
- •Type III
- •Type IV
- •Type V
- •Concepts of disease pathogenesis
- •Immune characteristics of the eye
- •Absence of lymphatic drainage
- •Intraocular microenvironment
- •Anterior Chamber-Associated Immune Deviation (ACAID)
- •Fas-Fas Ligand Interactions and Programmed Cell Death (Apoptosis)
- •Resident Ocular Cells and Immune System
- •Cytokines and Chemokines and the Eye
- •Oral Tolerance
- •Choroidal circulation and anatomy
- •Retina
- •Immunogenetics
- •Class I antigens
- •Class II and class III antigens
- •Histocompatibility lymphocyte antigens
- •Single-nucleotide polymorphisms (SNPs)
- •Epigenetics
- •Immune complex-mediated disease
- •Gene expression profiling
- •Tissue damage in the eye
- •T-cell responses and autoimmunity
- •T-cell receptor and the expression of disease
- •Ocular autoimmunity
- •Uveitogenic antigens
- •Retinal S-Antigen (Arrestin)
- •Interphotoreceptor Retinoid-Binding Protein
- •Recoverin
- •Bovine Melanin Protein
- •Rhodopsin
- •Phosducin
- •Tyrosinase
- •Other Antigens
- •Endotoxin and Other Bacterial Antigens
- •Importance of Antigen Studies
- •Cell adhesion molecules and their role in lymphocyte homing and in disease
- •Immune responses to invading viruses and parasites
- •Suggested Readings
- •References
- •Medical History in the Patient with Uveitis
- •References
- •Sample Uveitis Questionnaire
- •FAMILY HISTORY
- •SOCIAL HISTORY
- •PERSONAL MEDICAL HISTORY
- •MEDICAL HISTORY
- •Examination of the Patient with Uveitis
- •Visual acuity
- •External examination
- •Pupils and extraocular muscles
- •Intraocular pressure measurement
- •Slit-lamp biomicroscopy
- •Conjunctiva
- •Cornea
- •Keratic Precipitates
- •Other Corneal Findings
- •Anterior chamber
- •Iris
- •Anterior chamber angle
- •Lens
- •Vitreous
- •Retina and choroid
- •Optic nerve
- •References
- •Development of a Differential Diagnosis
- •Forming a differential diagnosis
- •Classifying uveitis
- •Is the disease acute or chronic?
- •Is the inflammation granulomatous or nongranulomatous?
- •Is the disease unilateral or bilateral?
- •Where is the inflammation located in the eye?
- •What are the demographics of the patient?
- •What associated symptoms does the patient have?
- •What associated signs are present on physical examination?
- •What is the time course of the disease and response to previous therapy?
- •Case 4-1
- •Case 4-2
- •References
- •Diagnostic Testing
- •Pretest likelihood of disease
- •Receiver operating characteristic (ROC) curve
- •Diagnostic tests for uveitis
- •Laboratory tests
- •Image analysis
- •Skin testing
- •Tissue samples
- •Ancillary ophthalmic tests
- •Electrophysiology
- •Laser interferometry
- •Fluorescein angiography
- •Indocyanine green
- •Laser flare photometry
- •Optical coherence tomography
- •High-frequency ultrasound biomicroscopy and multifrequency ultrasound
- •Fundus autofluorescence
- •Other diagnostic tests
- •Polymerase chain reaction (PCR)
- •Rapid tests for herpes simplex and herpes zoster
- •Bone mineral density studies
- •Genetic testing for steroid-induced glaucoma
- •Neurologic tests
- •References
- •Evidence-Based Medicine in Uveitis
- •Study design
- •Clinical trials in uveitis
- •References
- •Philosophy, Goals, and Approaches to Medical Therapy
- •Goals and philosophy
- •Pain, photophobia, and discomfort
- •Degree and location of inflammatory disease
- •Evaluation of visual acuity and prospect of reversibility
- •Follow-up procedures and standardization of observations
- •General health and age of patient
- •Patient reliability, preferences, and understanding
- •Nonsurgical therapeutic options
- •Corticosteroids
- •Mode of Action
- •Preparations, Dosage Schedules, and Complications
- •Ozurdex.
- •Secondary Effects
- •Cytotoxic agents
- •Alkylating agents
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Antimetabolites
- •Azathioprine
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Mycophenolate mofetil
- •Methotrexate
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Ciclosporin
- •Mode of Action
- •Dosages and Indications
- •Secondary Effects
- •Tacrolimus
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Lx 211 (Voclosporin)
- •Rapamycin
- •Mode of Action
- •Indications and Dosages
- •Toxicity
- •Antibodies and monoclonal antibodies
- •Daclizumab
- •Etanercept
- •Infliximab (Remicade)
- •Adalimumab (Humira)
- •Efalizumab (Raptiva)
- •Rituximab (Rituxan)
- •Anakinra (Kineret)
- •Alemtuzumab (Campath-1H)
- •Abatacept (Orencia)
- •Intravenous immunoglobulin therapy
- •Oral tolerance
- •Interferon-α
- •Antiviral therapy
- •Aciclovir
- •Ganciclovir
- •Valaciclovir
- •Famciclovir
- •Foscarnet
- •Combined ganciclovir and foscarnet
- •Cidofovir
- •Fomivirsen
- •Colchicine
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Mydriatic and cycloplegic agents
- •Antitoxoplasmosis therapy
- •Other therapeutic approaches
- •Immunostimulators
- •Plasmapheresis
- •Nonsteroidal antiinflammatory agents
- •References
- •Role of Surgery in the Patient with Uveitis
- •Considerations
- •Removal of band keratopathy
- •Corneal transplantation
- •Cataract surgery
- •Glaucoma surgery
- •Treatment of vitreoretinal disease
- •Laser treatment
- •Photodynamic therapy
- •Diagnostic surgery
- •Anterior chamber paracentesis
- •Chorioretinal biopsy
- •Subretinal surgery
- •Case 8-1
- •References
- •Bacterial and Fungal Diseases
- •Introduction
- •Leprosy
- •Clinical findings
- •Immunology and pathology
- •Therapy
- •Tuberculosis
- •Systemic disease
- •Ocular disease
- •Diagnosis
- •Therapy
- •Other bacterial infections
- •Brucellosis
- •Whipple’s disease
- •Treatment and prognosis
- •Chronic granulomatous disease
- •Fungal disease
- •Neuroretinitis
- •References
- •Spirochetal Diseases
- •Spirochetal infections and the eye
- •Spirochetes
- •Definition
- •Venereal treponemal diseases
- •Syphilis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Primary syphilis.
- •Secondary syphilis.
- •Latent syphilis.
- •Tertiary syphilis.
- •Benign tertiary syphilis.
- •Cardiovascular syphilis.
- •Neurosyphilis.
- •Congenital syphilis.
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •General recommendations.
- •Approach to Syphilis in Patients with AIDS
- •Nonvenereal treponematoses
- •Endemic syphilis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Yaws and pinta
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Borrelia infection
- •Lyme disease
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Relapsing fever
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Leptospirosis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Weil’s disease
- •Diagnosis
- •Prognosis
- •Treatment
- •Case 10-1
- •References
- •Acquired Immunodeficiency Syndrome
- •Human immunodeficiency virus
- •Epidemiology
- •Diagnosis
- •HIV disease
- •HIV therapy
- •Ocular manifestations of HIV infection
- •Ocular infection
- •Cytomegalovirus retinitis
- •Progression
- •CMV retinitis in the era of highly active antiretroviral therapy
- •Treatment
- •Intravitreal ganciclovir implant
- •Current therapeutic approach to CMV retinitis in the era of HAART
- •Retinal detachment
- •Prognosis
- •Immune recovery uveitis
- •Herpes zoster
- •Pneumocystis jirovecii choroiditis
- •Mycobacterium avium-intracellulare choroiditis
- •Other diseases
- •Drug-related ocular inflammation
- •Case 11-1
- •Case 11-2
- •References
- •Acute retinal necrosis
- •Epidemiology
- •Clinical features
- •Etiology
- •Differential diagnosis
- •Therapy
- •Progressive outer retinal necrosis
- •Diagnosis
- •Differential diagnosis
- •Etiology
- •Therapy
- •Case 12-1
- •Case 12-2
- •References
- •Other Viral Diseases
- •Herpes simplex virus kerititis and keratouveitis
- •Pathogenesis
- •Diagnosis
- •Treatment
- •Herpes zoster ophthalmicus
- •Treatment
- •West Nile virus
- •Epidemiology
- •Diagnosis
- •Clinical description
- •Ophthalmic manifestations
- •Treatment
- •Prognosis
- •Other viral infections
- •Human T-lymphotropic virus type I
- •Case 13-1
- •References
- •Ocular Toxoplasmosis
- •Organism
- •Clinical manifestations
- •Systemic
- •Ocular
- •Decreased Vision
- •Loss of Vision
- •Effects in immunocompromised host
- •Histopathology and immune factors
- •Immune response
- •Inflammatory response
- •Methods of diagnosis
- •Pregnancy
- •Other methods
- •Congenital versus acquired disease
- •Therapy
- •Additional therapeutic approaches
- •Case 14-1
- •Case 14-2
- •Case 14-3
- •Case 14-4
- •References
- •Ocular Histoplasmosis
- •Systemic findings
- •Ocular appearance
- •‘Histo’ spots
- •Maculopathy
- •Peripapillary pigment changes
- •Clear vitreous
- •Etiology and immunology
- •Nonsurgical therapies
- •Laser therapy
- •Subretinal surgery
- •References
- •Toxocara canis
- •Ocular manifestations
- •Histopathology and immune factors
- •Enzyme-linked immunoabsorbent assay
- •Treatment
- •Case 16-1
- •References
- •Onchocerciasis and Other Parasitic Diseases
- •Onchocerciasis
- •Clinical appearance
- •Immune characteristics
- •Therapy
- •Giardiasis
- •Ophthalmomyiasis
- •Cysticercosis
- •Caterpillar hairs
- •Amebiasis
- •Diffuse unilateral subacute neuroretinitis (DUSN)
- •Malaria
- •Seasonal hyperacute panuveitis (SHAPU)
- •References
- •Postsurgical Uveitis
- •Acute bacterial endophthalmitis
- •Chronic bacterial endophthalmitis
- •Fungal endophthalmitis
- •Endogenous endophthalmitis
- •Lens-induced uveitis
- •Toxic anterior segment syndrome (TASS)
- •Laser-induced uveitis
- •Case 18-1
- •References
- •Anterior Uveitis
- •Epidemiology
- •Clinical description
- •Idiopathic anterior uveitis
- •Diagnostic workup
- •Treatment
- •HLA-B27–associated anterior uveitis
- •Epidemiology
- •Demographics and clinical findings
- •Etiology
- •HLA-B27–associated anterior uveitis with systemic disease
- •Ankylosing spondylitis
- •Etiology
- •Treatment
- •Reactive arthritis (Reiter’s syndrome)
- •Juvenile idiopathic arthritis
- •Diagnosis
- •Pathology
- •Differential diagnosis
- •Treatment and prognosis
- •Psoriatic arthropathy
- •Inflammatory bowel disease
- •Whipple’s disease
- •Disease associations
- •Fuchs’ heterochromic iridocyclitis
- •Etiology
- •Treatment and prognosis
- •Kawasaki disease
- •Tubulointerstitial nephritis and uveitis syndrome (TINU)
- •Pathogenesis
- •Glaucomatous cyclitic crisis
- •Schwartz syndrome
- •Anterior segment ischemia
- •Lens-induced uveitis
- •Anterior uveitis associated with AIDS
- •Other disease associations
- •References
- •Scleritis
- •Episcleritis
- •Scleritis
- •Disease associations
- •Other causes of scleritis
- •Diagnostic testing
- •Pathogenesis
- •Differential diagnosis
- •Treatment
- •References
- •Intermediate Uveitis
- •Epidemiology
- •Clinical manifestations
- •Prognosis
- •Differential diagnosis
- •Multiple sclerosis
- •Etiology
- •Treatment
- •Corticosteroids
- •Immunosuppressive agents
- •Surgery
- •Case 21-1
- •Case 21-2
- •References
- •Sarcoidosis
- •Epidemiology
- •Etiology
- •Clinical manifestations
- •Anterior uveitis
- •Posterior segment findings
- •Systemic involvement
- •Pathology
- •Diagnosis
- •Treatment
- •Case 22-1
- •References
- •Sympathetic Ophthalmia
- •Clinical appearance and prevalence
- •Classic presentation
- •Sequelae
- •Tests and immunologic characteristics
- •Dalen–fuchs nodules
- •Preservation of the choriocapillaris
- •Therapy
- •Corticosteroids
- •Immunosuppressive agents
- •Case 23-1
- •Case 23-2
- •References
- •Vogt–Koyanagi–Harada Syndrome
- •Clinical aspects
- •Systemic findings
- •Ocular findings
- •Course of disease
- •Laboratory tests, etiology, and histopathology
- •Antigen-specific and immune responses
- •Vogt–Koyanagi–Harada syndrome versus sympathetic ophthalmia
- •Therapy
- •Cataract extraction
- •Case 24-1
- •Case 24-2
- •References
- •Birdshot Retinochoroidopathy
- •Clinical manifestations
- •Ocular examination and ancillary clinical tests
- •Tests, histology and etiology
- •Therapy
- •Case 25-1
- •Case 25-2
- •References
- •Behçet’s Disease
- •Clinical manifestations
- •Oral aphthous ulcers
- •Skin lesions
- •Genital ulcers
- •Ocular disease
- •Retinal disease
- •Complications
- •Minor criteria
- •Arthritis
- •Vascular alterations
- •Neurologic involvement (neuro-Behçet’s disease)
- •Immunologic and histologic considerations
- •Role of T cells (but other cells count too!)
- •HLA typing and single nucleotide polymorphisms (SNPs)
- •Therapy
- •Systemic corticosteroids
- •Cytotoxic and antimetabolic agents
- •Colchicine
- •Interferon-α
- •Ciclosporin and tacrolimus (FK506)
- •Anti-TNF therapy (infliximab)
- •Other approaches
- •Case 26-1
- •Case 26-2
- •Case 26-3
- •References
- •Retinal Vasculitis
- •Clinical characteristics
- •Ocular vasculitic disorders without systemic disease
- •Eales’ disease
- •Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN syndrome)
- •Frosted branch angiitis
- •Scleritis
- •Ocular vasculitic disorders with systemic disease
- •Systemic lupus erythematosus
- •Polyarteritis nodosa
- •Wegener’s granulomatosis
- •Whipple’s disease
- •Inflammatory bowel disease
- •Autoantibodies to Sjögren’s syndrome A antigen
- •Retinal vein occlusion
- •Relapsing polychondritis
- •Viral diseases
- •Multiple sclerosis
- •Tuberculosis
- •Rheumatoid arthritis
- •Kikuchi–Fujimoto disease
- •Susac syndrome
- •Sweet syndrome
- •References
- •Serpiginous Choroidopathy
- •Clinical features
- •Pathology
- •Etiology
- •Differential diagnosis
- •Therapy
- •Case 28-1
- •Case 28-2
- •Case 28-3
- •References
- •White-Dot Syndromes
- •Multiple evanescent white-dot syndrome
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Multifocal choroiditis and panuveitis
- •Clinical findings
- •Punctate inner choroidopathy
- •Laboratory findings
- •Therapy
- •Acute retinal pigment epitheliitis
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Acute posterior multifocal placoid pigment epitheliopathy
- •Clinical findings
- •Etiology
- •Therapy
- •Subretinal fibrosis and uveitis syndrome
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Acute zonal occult outer retinopathy (AZOOR) and the azoor complex diseases
- •Case 29-1
- •Case 29-2
- •Case 29-3
- •References
- •Masquerade Syndromes
- •Intraocular lymphoma
- •Non-Hodgkin’s lymphoma of central nervous system
- •Diagnosis
- •Treatment
- •Systemic Non-Hodgkin’s lymphoma metastatic to eye
- •Lymphoid hyperplasia of uvea
- •Other malignant processes manifesting as uveitis
- •Paraneoplastic syndromes
- •Multiple sclerosis
- •Other nonmalignant conditions
- •References
- •Introduction
- •Age-related macular degeneration
- •Animal work
- •Animal laser model
- •Ccl2 and Ccr2 knockout model
- •Ccl2 and Cx3cr1 double knockout model
- •CEP induced AMD-like disease
- •Human data
- •Autoimmunity
- •Gene associations
- •Macrophages and other cells
- •Histopathology
- •The downregulatory immune environment
- •Should we consider immunotherapy?
- •Diabetic retinopathy
- •Diabetes and the immune process
- •Animal work
- •Human observations
- •Can we begin to think about immune therapy for diabetes and diabetic retinopathy?
- •Glaucoma
- •Autoantibodies and glaucoma
- •Cellular immunity and glaucoma
- •Can immune intervention help alter the course of glaucoma?
- •References
- •Index
P a r t 4 Infectious uveitic conditions 16
Key concepts
•Toxocariasis is typically found in children, with the average age at diagnosis estimated to be 7.5 years.
•ELISA is the most reliable and readily available test for the evaluation of antibodies directed against this organism.
•If medical therapy is considered, anthelmintic drugs such as thiabendazole or diethylcarbamazine are frequently used, and prednisone can be used to reduce the secondary inflammatory response.
Nematode infections of the eye have been noted for some time; Calhoun,1 in 1937, observed a larva in the anterior chamber of an 8-year-old boy that ultimately was resorbed. By its description it was thought to be an ascarid. In 1950, Wilder2 reported on 24 patients in whom eyes enucleated for suspected retinoblastoma were found to have nematodes. Four of these lesions were later determined by Nichols3 to be caused by Toxocara canis. Over the years, this entity has been recognized to cause a disorder with potentially serious consequences for vision.
T. canis is an ascarid (i.e., a member of the Ascariditae family) that can only complete its lifecycle in the dog. An adult dog can acquire the infection by ingesting eggs with stage I encapsulated larvae that are found in the soil; by ingesting second stage larvae from infected meat (mice, rabbits, etc.); or by ingesting advanced-stage larvae from the feces of prenatally infected pups.4 In some parts of the United States toxocariasis is found in 100% of puppies less than 6 months of age.5 Eggs in the intestine will ultimately hatch, and the larvae will migrate out of the intestine to all parts of the body. Most will encyst as stage II larvae and not develop further. However, pregnancy will reactivate some of these dormant larvae, allowing them to re-enter the bloodstream and pass through the placenta to infest the growing pups. At birth, the larvae will migrate to the lungs and become stage III. These can be coughed up and then swallowed, whereupon these larvae develop into stage IV and ultimately into the adult worm. These adult worms will lay massive numbers of eggs that pass out of the host in the feces. Humans enter the pathway when they ingest soil, food, or other materials contaminated with the eggs. A survey of sandpits in parks in Japan found Toxocara eggs in 12 of 13 surveyed. The eggs were present both on the surface and in the depths of the sand.6 Once in the human intestine the stage II larva will enter the bloodstream, migrating
Toxocara canis
Robert B. Nussenblatt
throughout the body until the vascular lumen becomes small enough to block its progress. At this point the larva bores into the tissue and encysts. In addition to the eye, such cysts are frequently found in the brain, liver, and lungs. Because the larvae cannot migrate out of the human lungs, the life cycle ends at the stage II larval state, and Toxocara eggs will not be found in the feces of infected persons.
The encysted larvae may stay dormant without causing any clinically overt symptoms, although they are present in large numbers. However, one encysted larva in the eye can lead to serious visual disturbance. An acute systemic disease (visceral larval migrans [VLM]) is due to the migration of the stage II larva of T. canis.
T. canis infestation is associated with fever, pulmonary symptoms such as a dry, hacking cough or asthma-like attacks, splenomegaly and hepatomegaly, skin lesions, neurologic symptoms such as convulsions, and a meningitic picture.
T. canis is an ubiquitous parasite found worldwide. The incidence of infected puppies has been estimated to vary from 33% in London to 98% in Columbus, Ohio, to 100% in Brisbane, Australia.7 In one case–control study comparing 24 ageand sex-matched patients with VLM with control subjects, 23 of the patients with VLM had had dogs in their homes some time before their illness, and an association with puppies in households of patients with VLM within 1 year of onset was statistically significant.8
The disease is thought to be fairly uncommon in the devleoped world. At the Francis I. Proctor Foundation at the University of California, San Francisco, over a 20-year period, there were 22 cases out of 22 185 seen (Table 16-1), In an article9 estimating the prevalence of T. canis in Ireland, 120 00 participants were surveyed, and a prevalence of 6.6 cases/100 000 was calculated (Table 16-2). This rose to 9.7/100 000 if the cases thought to be highly suspect plus those diagnosed were included. The highest rate of seropositivity to Toxocara in adults seems to be on the island of Réunion, with a rate of 92.8%.10 It should be mentioned here that another member of the Ascariditae family, Toxocara cati, also needs to be considered in the differential diagnosis.11
Ocular manifestations
Toxocariasis is typically found in children; the average age of diagnosis is estimated to be 7.5 years, with a range from 2 to 31 years,12 and 80% of patients are under 16.13 It is still a diagnosis that should be considered in adults, such as the case reported in a 36-year-old woman.14 Yokoi and
Part 4 • Infectious Uveitic Conditions
Chapter 16 Toxocara canis
Table 16-1 Demographics and other information on Toxocara patients seen at the Proctor Foundation, UCSF. (From Stewart JM, et al. Prevalence, clinical features, and causes of vision loss among patients with ocular toxocariasis. Retina 2005; 25: 1005–13, with permission.)
Variable |
Finding |
||
Gender |
|
|
|
|
|
|
|
|
Male |
10 |
(45.5) |
|
|
|
|
|
Female |
12 |
(54.5) |
|
|
|
|
Ethnicity |
|
|
|
|
|
|
|
|
Non-Hispanic, white |
15 |
(68.1) |
|
|
|
|
|
Hispanic |
3 |
(13.6) |
|
|
|
|
|
Asian |
4 |
(18.1) |
|
|
|
|
Residence |
|
|
|
|
|
|
|
|
United States |
20 |
(90.9) |
|
|
|
|
|
California |
18 |
(81.8) |
|
|
|
|
|
International |
2 |
(9.1) |
|
|
|
|
Opthalmologist referral |
22 |
(100) |
|
|
|
|
|
Puppy/kitten exposure |
18 |
(81.8) |
|
|
|
|
|
Mean/median age at presentation (range) (yrs) |
|
|
|
|
|
||
All patients |
16.5/14 (1–37) |
||
|
|
|
|
|
Male |
15.3/11.5 (3–34) |
|
|
|
|
|
|
Female |
17.4/17.5 (1–37) |
|
|
|
|
|
Mean/median age from onset to presentation |
|
|
|
(range) (months) |
|
|
|
|
|
||
All patients |
18.8/5.5 (<1–212) |
||
|
|
|
|
|
Male |
7.9/6.3 (<1–22) |
|
|
|
|
|
|
Female |
28/5.5 (<1–212) |
|
|
|
|
|
colleagues15 reported this entity in 34 adults. Although exceptions have certainly been reported, this tends to be a uniocular disorder. The real prevalence of this disease may be underestimated because most reports dealing with blinding disorders chose patients with 6/60 or worse visual acuity in the best eye, and this disorder is typically unilateral.16 However, Benitez del Castillo and associates17 reported a bilateral occurrence of T. canis infestation in a patient who had a positive Witmer quotient for the parasite in both eyes.
Several ‘typical’ ocular presentations have been recognized. Probably the most common is a granuloma either in the posterior pole or in the periphery. This is presumed to arise after a stage II larva has been lodged in the choroid and becomes encysted.18 The lesion itself will be raised and whitish in color, with a width of 0.75 to 2 or 3 disc diameters (Fig. 16-1). In the report19 reviewing the 22 cases seen at the
Figure 16-1. Toxocara lesion in the macula of a 6-year-old girl. The choroidal lesion is raised, pushing the overlying retina upward; note epiretinal changes.
Table 16-2 Risk factors for toxocariasis in a European population. (From Good B, et al. Ocular toxocariasis in schoolchildren. Clin Infect Dis 2004; 39(2): 173–8, with permission.)
Factor |
Patients, n/N (%)* |
Controls n/N (%)* |
OR (95% CI) |
p |
|||
Dog ownership ever |
10/11 |
(90.9) |
24/44 |
(54.5) |
7.6 |
(0.97–394.4) |
0.0552 |
|
|
|
|
|
|
||
Cat ownership ever |
4/9 (44.4) |
22/44 |
(50) |
0.55 (0.05–4.2) |
0.8214 |
||
|
|
|
|
|
|
|
|
Bird ownership ever |
3/9 (33.3) |
8/44 |
(18.2) |
2.2 |
(0.31–12.7) |
0.5248 |
|
|
|
|
|
|
|
|
|
Dog ownership in the past 2 years |
9/11 |
(81.8) |
18/44 (40.9) |
5.5 |
(1.04–56.1) |
0.0422 |
|
|
|
|
|
|
|
||
Cat ownership in the past 2 years |
4/8 (50) |
20/44 |
(45.5) |
0.82 (0.08–6.7) |
1 |
||
|
|
|
|
|
|
|
|
Bird ownership in the past 2 years |
3/8 (37.5) |
4/44 |
(9.1) |
4.1 |
(0.54–28.1) |
0.1884 |
|
|
|
|
|
|
|
|
|
Wheeze in the past 12 months |
4/11 |
(36.4) |
8/44 |
(18.2) |
2.5 |
(0.43–13.3) |
0.3687 |
|
|
|
|
|
|
|
|
Asthma |
3/11 |
(27.3) |
3/44 |
(6.8) |
8.9 |
(0.62–498.4) |
0.1312 |
|
|
|
|
|
|
|
|
Eczema |
1/11 |
(9.1) |
4/44 |
(9.1) |
1 (0.02–14.1) |
1 |
|
|
|
|
|
|
|
|
|
Hayfever |
3/11 |
(27.3) |
7/44 |
(15.9) |
2.3 |
(0.25–20.0) |
0.6149 |
|
|
|
|
|
|
|
|
Convulsion |
4/10 |
(40) |
1/44 |
(2.3) |
16 (1.58–788) |
0.0134 |
|
|
|
|
|
|
|
||
Geophagia |
5/9 (55.6) |
4.44 (9.1) |
8.2 |
(1.4–62.2) |
0.0183 |
||
|
|
|
|
|
|
|
|
Additional matching factors were age, gender, and urban/rural residence (patients, n = 11; controls n = 44). *Number positive for the factor/replying to the question.
220
Proctor Foundation mentioned earlier, 50% presented with a peripheral retinal granuloma and 25% as macular lesions. This diagnosis must also be considered in the differential diagnosis of leukokoria because the lesion may become very large, encompassing a large portion of the vitreal cavity, and look suspiciously like a retinoblastoma. The disorder is frequently associated with a massive vitritis, probably the result of the release of highly immunogenic antigens from a dead worm.
Live larvae have been observed in the retinal vessels.20 Another recognized presentation of this entity is a peripheral retinitis, which is thought to be the result of a larva lodging in the peripheral retinal vasculature.
A hypopyon uveitis can be seen with any of these posterior pole manifestations. Fuchs’ heterochromia has been reported associated with this entity, just as has been noted in cases of ocular toxoplasmosis21 (Fig. 16-2).
A less common presentation of T. canis infestation in the eye is optic nerve disease;22,23 Brown and Tasman24 reported an 11-year-old child with a presumed toxocaral neuroretinitis associated with a branch retinal artery obstruction. Karel and colleagues25 reported a patient in whom the Toxocara larva observed in a choroidal granuloma migrated into the lens through the posterior capsule.
Figure 16-2. Right eye with heterochromia in a 20-year-old woman. The right eye fundus had a peripheral lesion compatible with Toxocara.
(Reproduced with permission from Teyssot, Cassoux, Lehoang, Bodaghi, Fuchs, Heterochromic Cyclitis and Ocular Toxocariasis. Am J Ophthalmol 2005;139:915–916.)
Ocular manifestations
Five cases of ocular toxocariasis in adults were reported by Steahly and Mader,26 all with presentations similar to those seen in children. A recent report described a Toxocara lesion presenting as a vasoproliferative tumor in a 64-year-old man.27
As mentioned earlier, the most important alternative diagnosis to consider is retinoblastoma.28 Shields29 has written that T. canis endophthalmitis is the most common entity confused with retinoblastoma. Further, presumed ocular toxocariasis accounted for 26% of the pseudoretinoblastomas seen at the Oncology Service of the Wills Eye Hospital, Philadelphia. Children with retinoblastoma usually are younger than those with ocular toxocariasis, the vitreous is usually clear, and there may be a familial history of the disorder. Ultrasound,30 radiographs, or other imaging methods will usually help distinguish this entity from retinoblastoma because calcification is found frequently in retinoblastoma, although it has also been reported in some patients with toxocariasis.31 Using a standardized echographic approach, Wan and colleagues32 studied the eyes of 11 patients with toxocariasis. In 10 of them the following characteristics were found: a solid highly reflective mass; vitreous bands or membranes that extended from the mass to the posterior pole; and a traction retinal detachment or fold from the mass to the posterior pole (Fig. 16-3). The migration of the Toxocara larva in the retina has been tracked by the use of OCT and fluorescein angiography.33 OCT demonstrated larva to produce a highly reflective signature, moving in the nerve fiber layer (Fig. 16-4). Angiograms performed during this study showed severe inflammatory disease even before the presumed death of the organism.
The aqueous to serum lactate dehydrogenase ratio is >1 in patients with retinoblastoma, and the phosphoglucose to isomerase ratio should be >2 in eyes with retinoblastoma. Other diagnoses to consider include toxoplasmosis; primary hyperplastic primary vitreous; Coats’ disease; focal choroiditis from another cause, such as sarcoid; and retrolental fibroplasia.
Figure 16-3. Fundus photograph and fluorescein of an adult patient with ocular toxocariasis seen at the NEI. Note the lesion adjacent to the disc with fibrotic stalk extending towards the periphery. This is perhaps better seen on the angiogram. (Reproduced with permission from NEI.)
221
- #28.03.202681.2 Mб0Ultrasonography of the Eye and Orbit 2nd edition_Coleman, Silverman, Lizzi_2006.pdb
- #
- #
- #
- #28.03.202621.35 Mб0Uveitis Fundamentals and Clinical Practice 4th edition_Nussenblatt, Whitcup_2010.chm
- #
- #
- #28.03.202627.87 Mб0Vaughan & Asbury's General Ophthalmology 17th edition_Riordan-Eva, Whitcher_2007.chm
- #
- #
- #
